Does Ozempic Cause Gastroparesis? What the Evidence Shows

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Communication

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering about gastroparesis. This condition slows stomach emptying and has been reported in some patients using GLP-1 receptor agonists. Building on decades of drug safety research, this page reviews the clinical evidence and FDA communications regarding Ozempic and gastroparesis.

Ozempic Pharmacology and Gastrointestinal Adverse Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, has been associated with GLP-1 receptor agonists, including Ozempic, through both clinical trial data and post-marketing reports. This section examines the clinical presentation and diagnosis of gastroparesis, the pharmacology of Ozempic and its reported adverse effects, mechanistic pathways linking the drug to gastroparesis, and risk considerations for affected patients. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can lead to nutritional deficiencies, weight loss, and impaired quality of life. In the context of Ozempic use, gastrointestinal symptoms are common and often dose-dependent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The most common adverse reactions reported in ≥5% of patients treated with Ozempic include nausea, vomiting, diarrhea, abdominal pain, and constipation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specifically, in placebo-controlled trials, nausea occurred in 15.8% of patients on Ozempic 0.5 mg and 20.3% on Ozempic 1 mg, compared to 6.1% on placebo; vomiting occurred in 5.0% and 9.2% respectively, compared to 2.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, raising the question of whether Ozempic can induce or exacerbate this condition.

Mechanistic Pathways and Risk Considerations

Mechanistically, GLP-1 receptor agonists like semaglutide slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which is part of their therapeutic effect on glycemic control. However, this pharmacological action can become pathological in some individuals, leading to clinically significant delayed gastric emptying. The delay in gastric emptying is dose-dependent and more pronounced at the start of treatment or during dose escalation. The prescribing information for Ozempic lists pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease as serious adverse reactions, but does not explicitly list gastroparesis as a separate warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the high rates of nausea, vomiting, and abdominal pain—symptoms that can mimic or indicate gastroparesis—suggest a potential link. Risk considerations for patients include the adequacy of warnings regarding Ozempic and gastroparesis. The current labeling emphasizes gastrointestinal adverse reactions during dose escalation and notes that most patients who discontinue treatment do so due to these effects. However, there is no specific warning about gastroparesis as a distinct adverse event, which may leave patients and clinicians unaware of the possibility of developing this condition. For affected patients, causation considerations involve the timeline between exposure and documented harm. Gastrointestinal symptoms typically emerge during the first weeks of treatment or after dose increases, aligning with the known pharmacodynamics of semaglutide. In clinical trials, the majority of nausea, vomiting, and diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This temporal relationship supports a causal link, though individual susceptibility varies. Patients who develop persistent or severe gastrointestinal symptoms while on Ozempic should be evaluated for gastroparesis. Diagnostic confirmation via gastric emptying scintigraphy can help differentiate drug-induced gastroparesis from other causes. Management may include dose reduction, temporary discontinuation, or switching to an alternative therapy. The risk of gastroparesis appears to be dose-related, as higher doses of Ozempic (2 mg) were associated with a higher frequency of gastrointestinal adverse reactions compared to 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a clinical trial with 959 patients treated with Ozempic 1 mg or 2 mg once weekly for 40 weeks, no new safety signals were identified, but the trial duration may not capture long-term effects (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In summary, while Ozempic's prescribing information does not explicitly list gastroparesis as a warning, the high incidence of gastrointestinal adverse reactions—particularly nausea, vomiting, and abdominal pain—along with the drug's known mechanism of delaying gastric emptying, suggests a plausible causal pathway. Patients and clinicians should be vigilant for symptoms of gastroparesis, especially during dose escalation, and consider diagnostic evaluation if symptoms persist. The adequacy of current warnings may need reassessment to ensure that patients are fully informed of this potential risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning about Ozempic and gastroparesis?

The FDA has not issued a specific warning for gastroparesis as a separate adverse event in Ozempic's labeling, but the prescribing information highlights high rates of gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, which overlap with gastroparesis symptoms. The FDA's adverse event reporting system includes post-marketing reports of gastroparesis associated with GLP-1 receptor agonists, prompting ongoing evaluation.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone as part of its therapeutic mechanism. In some individuals, this effect becomes pathological, leading to clinically significant delayed gastric emptying (gastroparesis). The risk is dose-dependent and more pronounced during dose escalation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.